European Commission gives nod to Sandoz’s biosimilar to treat autoimmune disorders
Sandoz, a key player in generic and biosimilar medicines, announced that the European Commission (EC) has granted marketing authorization for Pyzchiva (biosimilar ustekinumab), developed and registered by Samsung Bioepis. According to the company’s …